Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Tuberculosis (Edinb) ; 87(6): 557-64, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17890156

ABSTRACT

Factors that relate to medium-term outcome in patients with pulmonary tuberculosis (PTB) who have completed the 2-month intensive phase of treatment are incompletely understood. The relationship between in vitro production of interferon-gamma (IFN-gamma), interleukins (ILs)-5 and -10 and drug levels determined after 2 months of drug therapy, to outcome at 24 months was studied prospectively. Cytokine concentrations were determined from culture supernatants after stimulation of whole blood with purified protein derivative (PPD) of Mycobacterium tuberculosis. Plasma concentrations of rifampin, isoniazid, pyrazinamide and ethambutol were determined by high-performance liquid chromatography. The treatment failure and relapse free survival probability was 0.54 (95% CI: 0.40-0.67) at 24 months. In multivariate analysis of parameters at 2 months the strongest positive associations with disease free survival were IFN-gamma response to PPD (p=0.002) and serum creatinine (p=0.001). Drug concentrations were not associated with outcome although rifampin exposure correlated with IFN-gamma response to PPD (p=0.0132). These data suggest that the ability to mount a recall immune response to M. tuberculosis may influence treatment outcome. The data support the idea to identify persons at risk of a poor treatment outcome by monitoring of the in vitro response to tuberculosis antigens.


Subject(s)
Antibiotics, Antitubercular/blood , Interferon-gamma/biosynthesis , Rifampin/blood , Tuberculosis, Pulmonary/blood , Adult , Antibiotics, Antitubercular/therapeutic use , Epidemiologic Methods , Female , Humans , Interleukin-10/biosynthesis , Interleukin-5/biosynthesis , Male , Middle Aged , Prognosis , Rifampin/therapeutic use , Treatment Failure , Treatment Outcome , Tuberculin/immunology , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/immunology
2.
Clin Vaccine Immunol ; 14(2): 198-200, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17182761

ABSTRACT

In 10-week-old infants vaccinated at birth with Japanese Mycobacterium bovis BCG, the number of dermal needle penetrations correlated positively with frequency of proliferating CD4(+) T cells in whole blood following BCG stimulation for 6 days but did not correlate with secreted cytokine levels after 7 h or interferon CD4(+) T-cell frequency after 12 h of BCG stimulation.


Subject(s)
BCG Vaccine/immunology , Infant, Newborn/immunology , Tuberculosis/prevention & control , Dose-Response Relationship, Immunologic , Humans , Infant , Tuberculosis/immunology
3.
J Infect Dis ; 193(4): 531-6, 2006 Feb 15.
Article in English | MEDLINE | ID: mdl-16425132

ABSTRACT

Vaccination with Mycobacterium bovis bacille Calmette-Guerin (BCG) has variable efficacy in preventing tuberculosis. Both BCG strain and route of administration have been implicated in determining efficacy; however, these variables are not considered in current clinical recommendations for vaccine choice. We evaluated antigen-specific immunity after percutaneous or intradermal administration of Japanese BCG or intradermal administration of Danish BCG. Ten weeks after vaccination of neonates, percutaneous Japanese BCG had induced significantly higher frequencies of BCG-specific interferon- gamma -producing CD4(+) and CD8(+) T cells in BCG-stimulated whole blood than did intradermal Danish BCG. Similarly, percutaneous vaccination with Japanese BCG resulted in significantly greater secretion of the T helper 1-type cytokines interferon- gamma, tumor necrosis factor- alpha , and interleukin-2; significantly lower secretion of the T helper 2-type cytokine interleukin-4; and greater CD4(+) and CD8(+) T cell proliferation. Thus, BCG strain and route of neonatal vaccination confer different levels of immune activation, which may affect the efficacy of the vaccine.


Subject(s)
BCG Vaccine/administration & dosage , Immunity/drug effects , Infant, Newborn/immunology , T-Lymphocytes, Cytotoxic/drug effects , Antibodies, Bacterial/blood , BCG Vaccine/immunology , BCG Vaccine/pharmacology , Drug Administration Routes , Evaluation Studies as Topic , Female , Humans , Infant , Male , T-Lymphocytes, Cytotoxic/immunology , Vaccination/methods
4.
Immunology ; 105(3): 314-24, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11918693

ABSTRACT

This study evaluated whether different bacillus Calmette-Guérin (BCG) strains, routes of administration, vaccination age and percutaneous tools influenced immune responses to BCG vaccination in infants. Proliferative responses, cytokine production and cell-mediated cytotoxicity obtained in post-vaccinated children were compared to baseline cord bloods and unvaccinated 10-week-old infants. BCG vaccination generally induced strong lymphoproliferative and T helper type 1 (Th1)-type cytokine responses. There was a trend for greater responsiveness following the intradermal route of vaccination, with Japanese-172 strain and with delaying vaccination until 10 weeks. Cord mononuclear cells differentially stimulated the Th2-type cytokines interleukin-5 (IL-5) and IL-10 selectively in response to BCG, as compared to H37Rv or purified protein derivative stimulation. We document for the first time the generation of mycobacterium-specific cytotoxic T lymphocytes in neonates, following BCG vaccination. Cytotoxic activity correlated with the ratio of interferon-gamma to IL-5, aside from a single instance where use of the Biovac tool resulted in a striking dissociation selectively against H37Rv targets. These data have implications for correlates of protective immunity in design of vaccine studies.


Subject(s)
BCG Vaccine/immunology , Cytokines/biosynthesis , Infant, Newborn/immunology , T-Lymphocytes, Cytotoxic/immunology , Age Factors , BCG Vaccine/administration & dosage , Cell Division/immunology , Cytotoxicity, Immunologic , Fetal Blood/immunology , Humans , Immunity, Cellular , Immunization Schedule , Infant , Mycobacterium bovis/classification , Th1 Cells/immunology , Th2 Cells/immunology , Vaccination/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...